Subgroups analysis and circulating biomarkers evaluation of RESORT trial: A randomized phase II study in metastatic renal cell carcinoma (mRCC) patients (pts) to evaluate the efficacy of sorafenib after metastasectomy
2011 ◽
Vol 29
(15_suppl)
◽
pp. e15118-e15118
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 4547-4547
◽